vs
艾伯维（ABBV）与博士伦（BLCO）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是博士伦的11.8倍（$16.6B vs $1.4B）。艾伯维净利率更高（10.9% vs -4.1%，领先15.1%）。艾伯维同比增速更快（10.0% vs 9.8%）。艾伯维自由现金流更多（$4.9B vs $60.0M）。过去两年艾伯维的营收复合增速更高（16.2% vs 13.1%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
ABBV vs BLCO — 直观对比
营收规模更大
ABBV
是对方的11.8倍
$1.4B
营收增速更快
ABBV
高出0.3%
9.8%
净利率更高
ABBV
高出15.1%
-4.1%
自由现金流更多
ABBV
多$4.8B
$60.0M
两年增速更快
ABBV
近两年复合增速
13.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $1.4B |
| 净利润 | $1.8B | $-58.0M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 27.3% | 8.0% |
| 净利率 | 10.9% | -4.1% |
| 营收同比 | 10.0% | 9.8% |
| 净利润同比 | 8354.5% | -1833.3% |
| 每股收益（稀释后） | $1.02 | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVBLCO
| Q4 25 | $16.6B | $1.4B | ||
| Q3 25 | $15.8B | $1.3B | ||
| Q2 25 | $15.4B | $1.3B | ||
| Q1 25 | $13.3B | $1.1B | ||
| Q4 24 | $15.1B | $1.3B | ||
| Q3 24 | $14.5B | $1.2B | ||
| Q2 24 | $14.5B | $1.2B | ||
| Q1 24 | $12.3B | $1.1B |
净利润ABBVBLCO
| Q4 25 | $1.8B | $-58.0M | ||
| Q3 25 | $186.0M | $-28.0M | ||
| Q2 25 | $938.0M | $-62.0M | ||
| Q1 25 | $1.3B | $-212.0M | ||
| Q4 24 | $-22.0M | $-3.0M | ||
| Q3 24 | $1.6B | $4.0M | ||
| Q2 24 | $1.4B | $-151.0M | ||
| Q1 24 | $1.4B | $-167.0M |
毛利率ABBVBLCO
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVBLCO
| Q4 25 | 27.3% | 8.0% | ||
| Q3 25 | 12.1% | 7.4% | ||
| Q2 25 | 31.7% | -0.9% | ||
| Q1 25 | 28.0% | -7.3% | ||
| Q4 24 | -9.9% | 6.8% | ||
| Q3 24 | 26.5% | 3.6% | ||
| Q2 24 | 27.6% | 2.1% | ||
| Q1 24 | 22.7% | 0.5% |
净利率ABBVBLCO
| Q4 25 | 10.9% | -4.1% | ||
| Q3 25 | 1.2% | -2.2% | ||
| Q2 25 | 6.1% | -4.9% | ||
| Q1 25 | 9.6% | -18.6% | ||
| Q4 24 | -0.1% | -0.2% | ||
| Q3 24 | 10.8% | 0.3% | ||
| Q2 24 | 9.5% | -12.4% | ||
| Q1 24 | 11.1% | -15.2% |
每股收益（稀释后）ABBVBLCO
| Q4 25 | $1.02 | $-0.16 | ||
| Q3 25 | $0.10 | $-0.08 | ||
| Q2 25 | $0.52 | $-0.18 | ||
| Q1 25 | $0.72 | $-0.60 | ||
| Q4 24 | $-0.03 | $-0.00 | ||
| Q3 24 | $0.88 | $0.01 | ||
| Q2 24 | $0.77 | $-0.43 | ||
| Q1 24 | $0.77 | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $383.0M |
| 总债务越低越好 | $58.9B | $5.0B |
| 股东权益账面价值 | $-3.3B | $6.4B |
| 总资产 | $134.0B | $14.0B |
| 负债/权益比越低杠杆越低 | — | 0.78× |
8季度趋势，按日历期对齐
现金及短期投资ABBVBLCO
| Q4 25 | $5.3B | $383.0M | ||
| Q3 25 | $5.7B | $310.0M | ||
| Q2 25 | $6.5B | $266.0M | ||
| Q1 25 | $5.2B | $202.0M | ||
| Q4 24 | $5.6B | $305.0M | ||
| Q3 24 | $7.3B | $329.0M | ||
| Q2 24 | $13.2B | $285.0M | ||
| Q1 24 | $18.1B | $315.0M |
总债务ABBVBLCO
| Q4 25 | $58.9B | $5.0B | ||
| Q3 25 | $63.0B | $5.0B | ||
| Q2 25 | $63.0B | $5.0B | ||
| Q1 25 | $64.5B | $4.8B | ||
| Q4 24 | $60.3B | $4.8B | ||
| Q3 24 | $58.5B | $4.6B | ||
| Q2 24 | $58.0B | $4.6B | ||
| Q1 24 | $63.8B | $4.6B |
股东权益ABBVBLCO
| Q4 25 | $-3.3B | $6.4B | ||
| Q3 25 | $-2.6B | $6.4B | ||
| Q2 25 | $-183.0M | $6.4B | ||
| Q1 25 | $1.4B | $6.4B | ||
| Q4 24 | $3.3B | $6.5B | ||
| Q3 24 | $6.0B | $6.6B | ||
| Q2 24 | $6.8B | $6.5B | ||
| Q1 24 | $8.0B | $6.7B |
总资产ABBVBLCO
| Q4 25 | $134.0B | $14.0B | ||
| Q3 25 | $133.9B | $13.8B | ||
| Q2 25 | $137.2B | $13.8B | ||
| Q1 25 | $136.2B | $13.4B | ||
| Q4 24 | $135.2B | $13.5B | ||
| Q3 24 | $143.4B | $13.5B | ||
| Q2 24 | $141.9B | $13.3B | ||
| Q1 24 | $148.9B | $13.3B |
负债/权益比ABBVBLCO
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | 45.44× | 0.76× | ||
| Q4 24 | 18.15× | 0.74× | ||
| Q3 24 | 9.70× | 0.70× | ||
| Q2 24 | 8.56× | 0.71× | ||
| Q1 24 | 7.97× | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $136.0M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $60.0M |
| 自由现金流率自由现金流/营收 | 29.4% | 4.3% |
| 资本支出强度资本支出/营收 | 2.0% | 5.4% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | $-66.0M |
8季度趋势，按日历期对齐
经营现金流ABBVBLCO
| Q4 25 | $5.2B | $136.0M | ||
| Q3 25 | $7.0B | $137.0M | ||
| Q2 25 | $5.2B | $35.0M | ||
| Q1 25 | $1.6B | $-25.0M | ||
| Q4 24 | $7.0B | $22.0M | ||
| Q3 24 | $5.4B | $154.0M | ||
| Q2 24 | $2.3B | $15.0M | ||
| Q1 24 | $4.0B | $41.0M |
自由现金流ABBVBLCO
| Q4 25 | $4.9B | $60.0M | ||
| Q3 25 | $6.6B | $63.0M | ||
| Q2 25 | $4.9B | $-54.0M | ||
| Q1 25 | $1.4B | $-135.0M | ||
| Q4 24 | $6.8B | $-70.0M | ||
| Q3 24 | $5.2B | $94.0M | ||
| Q2 24 | $2.0B | $-57.0M | ||
| Q1 24 | $3.8B | $-26.0M |
自由现金流率ABBVBLCO
| Q4 25 | 29.4% | 4.3% | ||
| Q3 25 | 42.1% | 4.9% | ||
| Q2 25 | 31.7% | -4.2% | ||
| Q1 25 | 10.5% | -11.9% | ||
| Q4 24 | 44.7% | -5.5% | ||
| Q3 24 | 35.9% | 7.9% | ||
| Q2 24 | 14.0% | -4.7% | ||
| Q1 24 | 31.3% | -2.4% |
资本支出强度ABBVBLCO
| Q4 25 | 2.0% | 5.4% | ||
| Q3 25 | 2.4% | 5.8% | ||
| Q2 25 | 1.7% | 7.0% | ||
| Q1 25 | 1.8% | 9.7% | ||
| Q4 24 | 1.9% | 7.2% | ||
| Q3 24 | 1.7% | 5.0% | ||
| Q2 24 | 1.7% | 5.9% | ||
| Q1 24 | 1.6% | 6.1% |
现金转化率ABBVBLCO
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | 38.50× | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
